(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
-1.19% $ 23.25
@ $27.97
Emitido: 14 feb 2024 @ 15:13
Retorno: -16.88%
Señal anterior: feb 14 - 13:43
Señal anterior:
Retorno: 2.04 %
Live Chart Being Loaded With Signals
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology...
Stats | |
---|---|
Volumen de hoy | 317 415 |
Volumen promedio | 1.21M |
Capitalización de mercado | 1.19B |
EPS | $0 ( 2024-03-20 ) |
Próxima fecha de ganancias | ( $-0.730 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -9.01 |
ATR14 | $0.0280 (0.12%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-16 | Bizily Scott | Sell | 1 250 | Stock Option (Right To Buy) |
2024-04-16 | Bizily Scott | Sell | 500 | Stock Option (Right To Buy) |
2024-04-16 | Bizily Scott | Buy | 1 250 | Common Stock |
2024-04-16 | Bizily Scott | Buy | 500 | Common Stock |
2024-04-16 | Bizily Scott | Sell | 1 750 | Common Stock |
INSIDER POWER |
---|
31.08 |
Last 99 transactions |
Buy: 3 571 023 | Sell: 1 811 773 |
Volumen Correlación
4D Molecular Correlación
10 Correlaciones Más Positivas | |
---|---|
AFYA | 0.848 |
RMCF | 0.839 |
GOEV | 0.826 |
NTCT | 0.826 |
SLM | 0.821 |
IMGN | 0.818 |
TRMK | 0.817 |
NDAQ | 0.817 |
PRCT | 0.816 |
LSXMA | 0.816 |
10 Correlaciones Más Negativas | |
---|---|
ISDX | -0.838 |
ZIONP | -0.827 |
TRHC | -0.826 |
NVSAU | -0.823 |
KSICU | -0.822 |
IOAC | -0.821 |
GRBK | -0.815 |
XFIN | -0.813 |
VRIG | -0.812 |
BRIVU | -0.81 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
4D Molecular Correlación - Moneda/Commodity
4D Molecular Finanzas
Annual | 2023 |
Ingresos: | $20.72M |
Beneficio Bruto: | $14.97M (72.26 %) |
EPS: | $-2.58 |
FY | 2023 |
Ingresos: | $20.72M |
Beneficio Bruto: | $14.97M (72.26 %) |
EPS: | $-2.58 |
FY | 2022 |
Ingresos: | $3.13M |
Beneficio Bruto: | $-751 000 (-24.00 %) |
EPS: | $-3.12 |
FY | 2021 |
Ingresos: | $18.04M |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-11.09 |
Financial Reports:
No articles found.
4D Molecular
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico